SCHEMBL7375663

SCHEMBL7375663

CCOC(=O)CN(C)C(=O)CCCc1cccc(NC(=O)OC(C)(C)C)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
GLS O94925 1/20 0.36
GAA P10253 2/20 0.36
KDM4E B2RXH2 1/20 0.36
POLB P06746 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
MAPK8 P45983 1/20 0.34
CCR2 P41597 1/20 0.34
NR3C2 P08235 1/20 0.34
CHRNB2 P17787 1/20 0.34
CHRNB4 P30926 1/20 0.34
CHRNA3 P32297 1/20 0.34
CHRNA4 P43681 1/20 0.34
ALOX5 P09917 1/20 0.33
NPC1 O15118 1/20 0.33
LMNA P02545 1/20 0.33
TP53 P04637 1/20 0.33
MAPT P10636 1/20 0.33
PKM P14618 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7380720 0.80 GLS (0.41) MEN1KMT2AGLSGAAKDM4E
SCHEMBL5692965 0.80 SMN1; SMN2 (0.44) MEN1KMT2AGLSPOLBNPC1
SCHEMBL8492800 0.78 SMN1; SMN2 (0.42) KMT2AGAAKDM4ENPC1MAPT
SCHEMBL7377208 0.76 TSHR (0.33) GLSTSHRPTPRB
SCHEMBL23649504 0.76 NR3C2 (0.44) GLSKDM4EPOLBMAPK8CCR2
SCHEMBL4715049 0.76 NR3C2 (0.44) GLSMAPK8CCR2NR3C2CHRNB2
SCHEMBL30041417 0.76 NR3C2 (0.44) GLSKDM4EPOLBMAPK8CCR2
SCHEMBL7372453 0.76 GLS (0.44) GLSTDP1MAPK8CCR2NR3C2
SCHEMBL7375668 0.75 MEN1 (0.37) MEN1KMT2AGAAKDM4EPOLB
SCHEMBL6320838 0.75 NR3C2 (0.43) MEN1KMT2AGLSGAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6294549-B1 COMPOUNDS USEFUL FOR INHIBITING RESTENOSIS, ANGIOGENESIS, ATHEROSCLEROSIS, DIABETIC RETINOPATHY, MACULAR DEGENERATION, INFLAMMATION OR TUMOR GROWTH. MERCK & CO., INC. 2001-09-25 US disclosed
US-5952306-A INHIBITING THE BINDING OF FIBRINOGEN TO BLOOD PLATELETS AND INHIBITING THE AGGREGATION OF BLOOD PLATELETS; INHIBITING OSTEOCLAST CELLULAR ADHESION TO BONE SURFACES MERCK & CO., INC. (US) 1999-09-14 US disclosed
EP-0880511-A4 INTEGRIN RECEPTOR ANTAGONISTS MERCK & CO INC (US) 1999-06-16 EP disclosed
EP-0880511-A1 INTEGRIN RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 1998-12-02 EP disclosed
WO-1997026250-A1 INTEGRIN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1997-07-24 WO disclosed